Discuss the Study of EV - 103 BY Dr. Jonathan Rosenberg
Discussing the EV-103 Cohort K study, which resulted in the FDA approval of Enfortumab Vedotin + Pembrolizumab FDA Approval in the Cisplatin ineligible advanced urothelial carcinoma patients. In discussion with the lead author, Dr. Jonathan Rosenberg – Chief of Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center.
